MicroRNA-137 inhibits tumor growth and sensitizes chemosensitivity to paclitaxel and cisplatin in lung cancer

Oncotarget

Volumn 7, Issue 15, 2016, Pages 20728-20742

  Shen, Hua ^a   Wang, Lin ^a   Ge, Xin ^a   Jiang, Cheng Fei ^a   Shi, Zhu Mei ^a   Li, Dong Mei ^a   Liu, Wei Tao ^a   Yu, Xiaobo ^b   Shu, Yong Qian ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Chemosensitivity; Cisplatin; MiR 137; NUCKS1; Paclitaxel

Indexed keywords

CASEIN KINASE; CISPLATIN; MICRORNA; MICRORNA 137; NUCLEAR CASEIN KINASE; PACLITAXEL; PHOSPHOTRANSFERASE; PROTEIN NUCKS1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MIRN137 MICRORNA, HUMAN; NUCKS PROTEIN, HUMAN; NUCLEAR PROTEIN; PHOSPHOPROTEIN; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ENZYME REGULATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LUNG CANCER; LUNG CANCER CELL LINE; MALE; MIGRATION INHIBITION; MITOSIS INHIBITION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN RNA BINDING; PROTEIN TARGETING; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; LUNG TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BIOMARKERS, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NUCLEAR PROTEINS; PACLITAXEL; PHOSPHOPROTEINS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84964770908     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8011     Document Type: Article

References (42)

1. Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, Ward E, Wu XC, Eheman C, Anderson R, Ajani UA, Kohler B, Edwards BK. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. Journal of the National Cancer Institute. 2008; 100:1672-1694.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA: a cancer journal for clinicians. 2010; 60:277-300.
3. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006; 127:679-695.
4. Gao D, Vahdat LT, Wong S, Chang JC, Mittal V. Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer research. 2012; 72:4883-4889.
5. Goldman B. Multidrug resistance: can new drugs help chemotherapy score against cancer? Journal of the National Cancer Institute. 2003; 95:255-257.
6. Sato M, Shames DS, Gazdar AF, Minna JD. A translational view of the molecular pathogenesis of lung cancer. Journal of thoracic oncology. 2007; 2:327-343.
7. Behm-Ansmant I, Rehwinkel J, Izaurralde E. MicroRNAs silence gene expression by repressing protein expression and/or by promoting mRNA decay. Cold Spring Harbor symposia on quantitative biology. 2006; 71:523-530.
8. Ory B, Ramsey MR, Wilson C, Vadysirisack DD, Forster N, Rocco JW, Rothenberg SM, Ellisen LW. A microRNAdependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma. The Journal of clinical investigation. 2011; 121:809-820.
9. Wang Q, Chen W, Bai L, Chen W, Padilla MT, Lin AS, Shi S, Wang X, Lin Y. Receptor-interacting protein 1 increases chemoresistance by maintaining inhibitor of apoptosis protein levels and reducing reactive oxygen species through a microRNA-146a-mediated catalase pathway. The Journal of biological chemistry. 2014; 289:5654-5663.
10. Zhu X, Li Y, Xie C, Yin X, Liu Y, Cao Y, Fang Y, Lin X, Xu Y, Xu W, Shen H, Wen J. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6. International journal of cancer. 2014; 135:1286-1296.
11. Feng X, Wang Z, Fillmore R, Xi Y. MiR-200, a new star miRNA in human cancer. Cancer letters. 2014; 344:166-173.
12. Bitarte N, Bandres E, Boni V, Zarate R, Rodriguez J, Gonzalez-Huarriz M, Lopez I, Javier Sola J, Alonso MM, Fortes P, Garcia-Foncillas J. MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem cells. 2011; 29:1661-1671.
13. Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K. Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Molecular cell. 2010; 39:761-772.
14. Yang Y, Li F, Saha MN, Abdi J, Qiu L, Chang H. miR-137/197 induce apoptosis and suppress tumorigenicity by targeting MCL-1 in multiple myeloma. Clinical cancer research. 2015.
15. Liu LL, Lu SX, Li M, Li LZ, Fu J, Hu W, Yang YZ, Luo RZ, Zhang CZ, Yun JP. FoxD3-regulated microRNA-137 suppresses tumour growth and metastasis in human hepatocellular carcinoma by targeting AKT2. Oncotarget. 2014; 5:5113-5124. doi: 10.18632/oncotarget.2089.
16. Chen DL, Wang DS, Wu WJ, Zeng ZL, Luo HY, Qiu MZ, Ren C, Zhang DS, Wang ZQ, Wang FH, Li YH, Kang TB, Xu RH. Overexpression of paxillin induced by miR-137 suppression promotes tumor progression and metastasis in colorectal cancer. Carcinogenesis. 2013; 34:803-811.
17. Zhu X, Li Y, Shen H, Li H, Long L, Hui L, Xu W. miR-137 inhibits the proliferation of lung cancer cells by targeting Cdc42 and Cdk6. FEBS letters. 2013; 587:73-81.
18. Chen L, Wang X, Wang H, Li Y, Yan W, Han L, Zhang K, Zhang J, Wang Y, Feng Y, Pu P, Jiang T, Kang C, et al. miR-137 is frequently down-regulated in glioblastoma and is a negative regulator of Cox-2. European journal of cancer. 2012; 48:3104-3111.
19. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians. 2013; 63:11-30.
20. Pope M, Ashley MJ, Ferrence R. The carcinogenic and toxic effects of tobacco smoke: are women particularly susceptible? The journal of gender-specific medicine. 1999; 2:45-51.
21. Minna JD, Roth JA, Gazdar AF. Focus on lung cancer. Cancer cell. 2002; 1:49-52.
22. Stewart DJ. Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Critical reviews in oncology/hematology. 2010; 75:173-234.
23. Walaas SI, Ostvold AC, Laland SG. Phosphorylation of P1, a high mobility group-like protein, catalyzed by casein kinase II, protein kinase C, cyclic AMP-dependent protein kinase and calcium/calmodulin-dependent protein kinase II. FEBS letters. 1989; 258:106-108.
24. Maelandsmo GM, Ostvold AC, Laland SG. Phosphorylation of the high-mobility-group-like protein P1 by casein kinase-2. European journal of biochemistry/FEBS. 1989; 184:529-534.
25. Meijer L, Ostvold AC, Walass SI, Lund T, Laland SG. Highmobility-group proteins P1, I and Y as substrates of the M-phase-specific p34cdc2/cyclincdc13 kinase. European journal of biochemistry/FEBS. 1991; 196:557-567.
26. Ostvold AC, Norum JH, Mathiesen S, Wanvik B, Sefland I, Grundt K. Molecular cloning of a mammalian nuclear phosphoprotein NUCKS, which serves as a substrate for Cdk1 in vivo. European journal of biochemistry/FEBS. 2001; 268:2430-2440.
27. Wisniewski JR, Schwanbeck R. High mobility group I/Y: multifunctional chromosomal proteins causally involved in tumor progression and malignant transformation (review). International journal of molecular medicine. 2000; 6:409-419.
28. Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S, Skomedal H, Tu IP, Hernandez-Boussard T, et al. Gene expression patterns in ovarian carcinomas. Molecular biology of the cell. 2003; 14:4376-4386.
29. Thompson HG, Harris JW, Wold BJ, Quake SR, Brody JP. Identification and confirmation of a module of coexpressed genes. Genome research. 2002; 12:1517-1522.
30. Drosos Y, Kouloukoussa M, Ostvold AC, Grundt K, Goutas N, Vlachodimitropoulos D, Havaki S, Kollia P, Kittas C, Marinos E, Aleporou-Marinou V. NUCKS overexpression in breast cancer. Cancer cell international. 2009; 9:19.
31. Sargent LM, Ensell MX, Ostvold AC, Baldwin KT, Kashon ML, Lowry DT, Senft JR, Jefferson AM, Johnson RC, Li Z, Tyson FL, Reynolds SH. Chromosomal changes in high-and low-invasive mouse lung adenocarcinoma cell strains derived from early passage mouse lung adenocarcinoma cell strains. Toxicology and applied pharmacology. 2008; 233:81-91.
32. Corson TW, Huang A, Tsao MS, Gallie BL. KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. Oncogene. 2005; 24:4741-4753.
33. Kikuchi A, Ishikawa T, Mogushi K, Ishiguro M, Iida S, Mizushima H, Uetake H, Tanaka H, Sugihara K. Identification of NUCKS1 as a colorectal cancer prognostic marker through integrated expression and copy number analysis. International journal of cancer. 2013; 132: 2295-2302.
34. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW, Jr., Grant SC, Horn L, Jahan TM, et al. Non-small cell lung cancer, version 2.2013. Journal of the National Comprehensive Cancer Network: JNCCN. 2013; 11:645-653; quiz 653.
35. Azzoli CG, Baker S, Jr., Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. Journal of clinical oncology. 2009; 27:6251-6266.
36. Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Chan G, Kamath SG, Chen DT, Dressman H, Lancaster JM. MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecologic oncology. 2009; 113:249-255.
37. Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S, Hong L, Liu J, Fan D. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. International journal of cancer. 2008; 123:372-379.
38. Siemens H, Jackstadt R, Kaller M, Hermeking H. Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness. Oncotarget. 2013; 4:1399-1415. doi: 10.18632/oncotarget.1202.
39. Shi Z, Chen Q, Li C, Wang L, Qian X, Jiang C, Liu X, Wang X, Li H, Kang C, Jiang T, Liu LZ, You Y, et al. MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras. Neurooncology. 2014; 16:1341-1353.
40. Qian X, Yu J, Yin Y, He J, Wang L, Li Q, Zhang LQ, Li CY, Shi ZM, Xu Q, Li W, Lai LH, Liu LZ, et al. MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers. Cell cycle. 2013; 12:1385-1394.
41. Valeri N, Gasparini P, Braconi C, Paone A, Lovat F, Fabbri M, Sumani KM, Alder H, Amadori D, Patel T, Nuovo GJ, Fishel R, Croce CM. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proceedings of the National Academy of Sciences of the United States of America. 2010; 107:21098-21103.
42. Liu LZ, Zheng JZ, Wang XR, Jiang BH. Endothelial p70 S6 kinase 1 in regulating tumor angiogenesis. Cancer research. 2008; 68:8183-8188.